- Compugen ( NASDAQ: CGEN ) said that the Japan Patent Office granted a new composition of matter and use patent covering its anti-PVRIG, COM701 and backup anti-PVRIG antibodies.
- The Japanese patent No. 2017-562952 is expected to expire not before 2036.
- The company noted that in pre-clinical studies, blockade of PVRIG — a novel immune checkpoint — by COM701 has shown potent, reproducible enhancement of T cell activation, consistent with the desired mechanism of action of activating T cells in the tumor microenvironment to generate anti-tumor immune responses.
- CGEN +1.57% to $1.29 premarket Aug. 24
For further details see:
Compugen gets Japanese patent for COM701, anti-PVRIG antibodies